366 related articles for article (PubMed ID: 23508652)
1. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
[TBL] [Abstract][Full Text] [Related]
2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
3. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.
Blair NF; Brew BJ; Halpern JP
Neurology; 2012 Feb; 78(7):507-8. PubMed ID: 22302545
[No Abstract] [Full Text] [Related]
5. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
6. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
[TBL] [Abstract][Full Text] [Related]
7. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.
Phan-Ba R; Lommers E; Tshibanda L; Calay P; Dubois B; Moonen G; Clifford D; Belachew S
J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):224-6. PubMed ID: 22013244
[TBL] [Abstract][Full Text] [Related]
8. JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment.
Schippling S; Kempf C; Büchele F; Jelcic I; Bozinov O; Bont A; Linnebank M; Sospedra M; Weller M; Budka H; Martin R
Ann Neurol; 2013 Oct; 74(4):622-6. PubMed ID: 23868420
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
[TBL] [Abstract][Full Text] [Related]
10. The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
Baheerathan A; McNamara C; Kalam S; Rane N; Barwick TD; Grote H; Nicholas R
Neurology; 2018 Sep; 91(12):572-573. PubMed ID: 30224501
[No Abstract] [Full Text] [Related]
11. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
[TBL] [Abstract][Full Text] [Related]
12. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
13. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W
Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
Gheuens S; Smith DR; Wang X; Alsop DC; Lenkinski RE; Koralnik IJ
Neurology; 2012 May; 78(18):1390-3. PubMed ID: 22517104
[TBL] [Abstract][Full Text] [Related]
15. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
Wattjes MP; Verhoeff L; Zentjens W; Killestein J; van Munster ET; Barkhof F; van Eijk JJ
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1176-7. PubMed ID: 23695498
[No Abstract] [Full Text] [Related]
16. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
Langer-Gould A; Atlas SW; Green AJ; Bollen AW; Pelletier D
N Engl J Med; 2005 Jul; 353(4):375-81. PubMed ID: 15947078
[TBL] [Abstract][Full Text] [Related]
18. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
Havla J; Berthele A; Kümpfel T; Krumbholz M; Jochim A; Kronsbein H; Ryschkewitsch C; Jensen P; Lippmann K; Hemmer B; Major E; Hohlfeld R
Mult Scler; 2013 Aug; 19(9):1213-5. PubMed ID: 23124790
[TBL] [Abstract][Full Text] [Related]
19. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
Aly L; Yousef S; Schippling S; Jelcic I; Breiden P; Matschke J; Schulz R; Bofill-Mas S; Jones L; Demina V; Linnebank M; Ogg G; Girones R; Weber T; Sospedra M; Martin R
Brain; 2011 Sep; 134(Pt 9):2687-702. PubMed ID: 21908874
[TBL] [Abstract][Full Text] [Related]
20. Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy.
Calvi A; De Riz M; Pietroboni AM; Ghezzi L; Maltese V; Arighi A; Fumagalli GG; Jacini F; Donelli C; Comi G; Galimberti D; Scarpini E
Immunotherapy; 2014; 6(1):23-8. PubMed ID: 24341880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
